10x Genomics, Inc. — Director's Dealing 2019

Sep 16, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: 10x Genomics, Inc. (TXG)
CIK: 0001770787
Period of Report: 2019-09-16

Reporting Person: McAnear Justin J. (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-09-16	Stock Option (right to buy)	$5.04	J	600000	Disposed	2028-11-02	Class B Common Stock (600000)	Direct
2019-09-16	Stock Option (right to buy)	$5.04	J	600000	Acquired	2028-11-02	Class A Common Stock (600000)	Direct
2019-09-16	Stock Option (right to buy)	$11.48	J	20000	Disposed	2029-05-10	Class B Common Stock (20000)	Direct
2019-09-16	Stock Option (right to buy)	$11.48	J	20000	Acquired	2029-05-10	Class A Common Stock (20000)	Direct

Footnotes

F1: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering.

F2: One-fourth of the shares subject to the option vest on October 8, 2019 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. This option may be exercised prior to vesting, subject to the Issuer's right to repurchase unvested shares.

F3: One forty-eighth of the shares subject to the option vested on May 1, 2019 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.